What Does a Sustainable Affordability Model Look Like in the Current Landscape?

Key Takeaways

• IRA forces shift from access to gross‑to‑net protection
• PAP programs require continuous redesign and cap adjustments
• AI automation speeds hub services and therapy initiation
• ConnectiveRx expands dispensing‑pharmacy to improve margins
• Dynamic models protect revenue amid evolving regulatory landscape

Summary

Shivani Patel of ConnectiveRx explains how the Inflation Reduction Act forces pharmaceutical manufacturers to redesign patient‑assistance programs with a focus on gross‑to‑net protection rather than static access solutions. She emphasizes continuous program evaluation, cap adjustments, and alignment with channel‑distribution strategies to safeguard revenue. Automation and AI are accelerating hub‑to‑therapy timelines, while ConnectiveRx’s expanded dispensing‑pharmacy capabilities add margin‑friendly control. The conversation highlights that sustainable affordability now requires dynamic, data‑driven models that evolve with regulatory changes.

Pulse Analysis

The Inflation Reduction Act has upended traditional patient‑assistance thinking by inserting gross‑to‑net considerations into every affordability calculation. Manufacturers can no longer rely on static copay‑offset or coupon structures; instead they must treat PAPs as dynamic financial levers that respond to rebate forecasts, pricing reforms, and market‑share pressures. This regulatory pivot forces pharma companies to embed continuous monitoring and scenario planning into their revenue‑management teams, ensuring that patient access initiatives also safeguard net margins. Consequently, pricing negotiations now incorporate projected PAP spend, forcing sales teams to align discount structures with anticipated rebate recovery.

ConnectiveRx is leveraging automation and artificial intelligence to compress the hub‑to‑therapy timeline, turning what was once a weeks‑long coordination effort into a matter of days. Machine‑learning algorithms match patients with the optimal dispensing pharmacy, predict eligibility hurdles, and trigger real‑time adjustments to benefit designs. The company’s recent expansion of in‑house dispensing capabilities adds a margin‑friendly layer, allowing manufacturers to retain greater control over drug distribution while still meeting affordability commitments. Robust compliance protocols and encrypted data pipelines ensure that patient information remains protected throughout the automated workflow. These technology‑driven efficiencies translate into faster treatment starts and lower administrative overhead.

The broader implication for the industry is clear: sustainable affordability now hinges on agility, data, and integrated service models. Firms that institutionalize periodic PAP reviews, embed AI‑enabled hubs, and partner with dispensing networks will better protect gross‑to‑net spreads while delivering consistent patient access. As the IRA’s provisions evolve and additional cost‑containment measures emerge, this adaptive framework will become a competitive differentiator, enabling manufacturers to navigate price volatility without sacrificing market share or therapeutic outcomes. Integrating these models with emerging value‑based contracts further aligns payer incentives with clinical outcomes, reinforcing the business case for dynamic affordability.